他汀类药物相关抗HMGCR抗体介导坏死性肌病的研究进展  

Necrotizing Myopathy Related to Anti-3-hydroxy-3-methylglutaryl-coenzyme A Reductase Antibody

作　　者：焦宇琼 林洁[1] 蔡爽[1] 奚剑英[1] 朱雯华[1] 赵重波[1] 卢家红[1] 

机构地区：[1]复旦大学附属华山医院神经内科,200040

出　　处：《中国临床神经科学》2017年第2期191-197,共7页Chinese Journal of Clinical Neurosciences

摘　　要：抗3-羟基3-甲基戊二酰辅酶A还原酶(HMGCR)抗体介导的坏死性肌病是近年逐渐被认识的一类疾病,该病与他汀类药物的使用密切相关。患者具有坏死性肌病的一般特点,通过抗HMGCR抗体阳性与其他类型的坏死性肌病相鉴别。多数患者可通过激素联合其他免疫抑制剂治疗可控制病情。文中回顾了该病的发病机制、流行病学、临床特点、诊断及鉴别诊断、治疗等研究现状,以加强临床医生对该病的认识。Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase （HMGCR） antibody mediated necrotizing myopathy is gradually known by clinical doctors in recent years. Its incidence is low. Statins may be a triggering factor of this disease. Patients have the general characters of necrotizing myopathy, and can be distinguished from other kinds of necrotizing myopathy by anti-HMGCR antibody positive. Glucocorticoids are the most common initial immunosuppressive agent, but other kinds of immunosuppressants are often necessary. The etiology, epidemiology, clinical characteristics, diagnosis and treatment of anti-HMGCR antibody-mediated autoimmune necrotizing myopathy were reviewed.

关 键 词：他汀类药物 抗3-羟基3-甲基戊二酰辅酶A还原酶抗体 坏死性肌病 临床特点 诊断标准 治疗 

分 类 号：R746[医药卫生—神经病学与精神病学]